BidaskClub downgraded shares of Myriad Genetics, Inc. (NASDAQ:MYGN) from a buy rating to a hold rating in a research report report published on Thursday.

Other research analysts have also recently issued reports about the company. Jefferies Group LLC reaffirmed a hold rating and issued a $21.00 price target (up from $18.00) on shares of Myriad Genetics in a report on Wednesday, May 3rd. Zacks Investment Research raised Myriad Genetics from a hold rating to a buy rating and set a $28.00 price target for the company in a report on Monday, July 17th. Cowen and Company reissued a hold rating and set a $25.00 price objective on shares of Myriad Genetics in a report on Friday, July 14th. Piper Jaffray Companies reissued a hold rating and set a $22.00 price objective on shares of Myriad Genetics in a report on Friday, July 14th. Finally, J P Morgan Chase & Co reissued an underweight rating and set a $16.00 price objective on shares of Myriad Genetics in a report on Friday, June 30th. Five investment analysts have rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $21.77.

Shares of Myriad Genetics (NASDAQ:MYGN) traded up 1.93% during trading on Thursday, reaching $25.37. 650,070 shares of the company were exchanged. The stock has a market capitalization of $1.73 billion, a P/E ratio of 54.21 and a beta of 0.31. The stock has a 50-day moving average of $24.85 and a 200 day moving average of $20.44. Myriad Genetics has a 52-week low of $15.15 and a 52-week high of $31.50.

TRADEMARK VIOLATION WARNING: “BidaskClub Downgrades Myriad Genetics, Inc. (MYGN) to Hold” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/08/07/bidaskclub-downgrades-myriad-genetics-inc-mygn-to-hold.html.

Several institutional investors have recently bought and sold shares of MYGN. Albert D Mason Inc. raised its position in Myriad Genetics by 1.5% in the first quarter. Albert D Mason Inc. now owns 16,382 shares of the company’s stock valued at $315,000 after buying an additional 250 shares during the last quarter. Commerzbank Aktiengesellschaft FI raised its position in Myriad Genetics by 1.7% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 21,733 shares of the company’s stock valued at $417,000 after buying an additional 357 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in Myriad Genetics by 3.1% in the second quarter. Municipal Employees Retirement System of Michigan now owns 16,080 shares of the company’s stock valued at $416,000 after buying an additional 490 shares during the last quarter. Aperio Group LLC raised its position in Myriad Genetics by 4.6% in the second quarter. Aperio Group LLC now owns 12,129 shares of the company’s stock valued at $313,000 after buying an additional 534 shares during the last quarter. Finally, Creative Planning raised its position in Myriad Genetics by 11.8% in the first quarter. Creative Planning now owns 6,371 shares of the company’s stock valued at $122,000 after buying an additional 671 shares during the last quarter.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.